SOX11 and TP53 add prognostic information to MIPI in a homogenously treated cohort of mantle cell lymphoma – a Nordic Lymphoma Group study
Mantle cell lymphoma (MCL) is an aggressive B cell lymphoma, where survival has been remarkably improved by use of protocols including high dose cytarabine, rituximab and autologous stem cell transplantation, such as the Nordic MCL2/3 protocols. In 2008, a MCL international prognostic index (MIPI) w...
Main Authors: | , , , , , , , , , , , , , , |
---|---|
Format: | Online |
Language: | English |
Published: |
BlackWell Publishing Ltd
2014
|
Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4282019/ |